Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis Reports Decrease in Q2 Revenue Atop Widened Loss; June Lay Offs Played Role

NEW YORK, Aug. 6 (GenomeWeb News) - Exelixis yesterday reported a decrease in second-quarter revenue atop greater R&D spending and a significantly widened net loss.


Total receipts for the three months ended June 30 fell to $12.6 million from $13 million year over year. Exelixis blamed the fall-off on the end of a collaboration with Protein Design Labs, but said receipts were offset by milestone revenue from a drug target deal with Bristol-Myers Squibb.


R&D spending inched up to $34.4 million in the second quarter this year from $32.5 million one year ago.


Net loss swelled to $29.3 million, or $.41 per share, from $23.4 million, or $.39 per share, in the year-ago quarter. Exelixis said $1.7 million of the increase was due to "termination benefits" following a round of lay offs the company initiated in June. On June 30, the company laid off 62 people, or 11 percent of its workforce, mainly from R&D. Exelixis said it expects the cuts to save it "at least" $5 million for the balance of the year and $10 million in 2005 and "beyond."


Exelixis, based in South San Francisco, Calif., said it had around $170.3 million cash, equivalents, and short-term investments as of June 30.


The company said it expects revenue for the third quarter to be between $12 million and $11.5 million, and plans to end the year with $180 million in cash, equivalents, and short-term investments.


For more information, click here.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.